Background: Pre-clinical studies have shown that furosemide slows cancer cell growth by acting on the Na-K-2Cl transporter, particularly for gastric cancer cells. However, epidemiological studies have not investigated furosemide use and mortality in gastroesophageal cancer patients. Consequently, we conducted a population-based study to investigate whether furosemide use is associated with reduced cancer-specific mortality in esophageal/gastric cancer patients. Methods: A cohort of patients newly diagnosed with esophageal or gastric cancer between 1998 and 2013 were identified from English cancer registries and linked to the Clinical Practice Research Datalink to provide prescription records and the Office of National Statistics to provide death data up to September 2015. Time-dependant Cox-regression models were used to calculate hazard ratios (HRs) comparing cancer-specific mortality in furosemide users with non-users. Analyses were repeated restricting to patients with common furosemide indications (heart failure, myocardial infarction, edema or hypertension) to reduce potential confounding. Results: The cohort contained 2708 esophageal cancer patients and 2377 gastric cancer patients, amongst whom 1844 and 1467 cancer-specific deaths occurred, respectively. Furosemide use was not associated with reduced cancerspecific mortality overall (adjusted HR in esophageal cancer = 1.28, 95% CI 1.10, 1.50 and in gastric cancer = 1.27, 95% CI 1.08, 1.50) or when restricted to patients with furosemide indications before cancer diagnosis (adjusted HR in esophageal cancer = 1.07, 95% CI 0.88, 1.30 and in gastric cancer = 1.18, 95% CI 0.96, 1.46). Conclusions: In this large population-based cohort study, furosemide was not associated with reduced cancer-specific mortality in patients with esophageal or gastric cancer.
found with two subtypes, ubiquitous NKCC1 and kidney-specific NKCC2, both of which are sensitive to furosemide [9] .
Recently, evidence has emerged that the NKCC plays an important role in cancer cell growth. It has been shown that overexpression of the NKCC can induce cell proliferation [10, 11] . An in-vitro cell study found that NKCC1 expression was three times higher in poorly differentiated compared with moderately differentiated gastric adenocarcinoma cells [12] . This study also showed that furosemide reduced cell growth in poorly differentiated gastric adenocarcinoma cells, and suggested this action was via the inhibition of NKCC [12] . Consistently, NKCC1 was found to have higher expression in more poorly differentiated esophageal squamous-cell carcinoma (SCC) cases and depletion of NKCC1 inhibited cell proliferation [13] . Despite this preclinical evidence suggesting furosemide could slow gastroesophageal cancer progression, no studies have been conducted to investigate a potential association in humans.
Therefore, we conducted a large population-based cohort study to investigate whether furosemide use influences esophageal/gastric cancer-specific mortality.
Methods

Data source
Clinical Practice Research Datalink (CPRD) database is a primary care research database which covers nearly 11.3 million patients, accounting for approximately 6.9% of the UK population, and captures diagnoses, prescriptions and demographic information [14] . We obtained data from CPRD that was linked to the National Cancer Data Repository (NCDR) and the Office of National Statistics (ONS) mortality data. The NCDR contains cancer information from all English cancer registers, capturing diagnosis date, tumor characteristics and treatments. The ONS mortality data records cause and date of death.
Ethical approval for all purely observational research using CPRD data has been obtained from the East Midlands-Derby Research Ethics Service Committee (reference number: 05/MRE04/87). The study protocol was approved by The Independent Scientific Advisory of the Clinical Practice Research Datalink in 2015 (protocol number: 15_096RMn3).
Study design and population
A cohort of newly diagnosed esophageal and gastric cancer patients was ascertained from English cancer registries between 1998 and 2013 using International Classification of Disease (ICD) codes C15 and C16, respectively. Individuals with previous cancer (apart from non-melanoma skin cancer or in situ tumors) were excluded using a list of Read codes modified for use in the CPRD database [15] . All eligible cases were further classed as adenocarcinoma (using ICD for Oncology (ICD-O) morphology codes 8140-8573) or SCC (ICD-O 8050-8082). Deaths from esophageal or gastric cancer were identified up to September 2015 based upon the underlying cause of death (from the ONS mortality data) using ICD codes C15, C16 and C26. Therefore, participants were followed until the earliest following event occurred: 1) participants ended their registration with the general practitioner (GP); 2) last data collection from GP; 3) patients died; 4) September 2015 at which time ONS follow-up ended.
Definition of exposure
Furosemide was identified within GP prescription records based upon the British National Formulary. Overall, 78% of furosemide prescriptions were 40 mg, 20% were 20 mg. The daily defined doses (DDD) in each prescription were calculated by multiplying the quantity by the strength (in mg) and dividing by the mg in a DDD from the World Health Organization [16] .
Covariates
Lifestyle risk factors were obtained from GP records, including smoking status (never, former, current), alcohol consumption (never, former, current), and body mass index (BMI in kg/m 2 categorised as: underweight < 18.5; normal weight 18.5 to 25; overweight: 25 to 30 and obese: ≥ 30). For these lifestyle risk factors, we extracted the closest records before esophageal/gastric cancer diagnosis, and ignored records more than 10 years before the diagnosis. Comorbidities at any time before cancer diagnosis were identified from the CPRD database according to the Charlson Comorbidity Index, including AIDS, cerebrovascular disease, chronic pulmonary disease, congestive heart disease, dementia, diabetes, diabetes with complications, hemiplegia, mild liver disease, moderate liver disease, myocardial infarction (MI), peptic ulcer disease, peripheral vascular disease, renal disease and rheumatological disease [15] . Deprivation was determined from the patients' postcode based on the 2010 Index of Multiple Deprivation Score [17] . Also, furosemide indications including heart failure (HF) [18] , MI [19] , edema (Read code categories listed in Table 5 in Appendix) and hypertension [19] prior to cancer diagnosis were identified from the CPRD database using Read codes. Statin and aspirin use after diagnosis were also identified from GP records as previous studies have suggested these drugs could reduce mortality in patients with gastric or esophageal cancer [20, 21] . Patients using antihypertensive medications (diuretics, vasodilator antihypertensive drugs, centrally acting antihypertensive drugs, alpha-adrenoceptor blocking drugs, beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, renin inhibitors and calcium channel blockers) were identified from prescription records [22] .
Statistical analysis
Summary statistics and frequencies were determined for patient characteristics by furosemide use.
In the primary analyses, patients who died within 6 months were excluded as it seems unlikely that medication use after diagnosis could benefit such patients. Therefore, individuals were followed from 6 months after diagnosis to cancer-specific death or censoring. Furosemide use was treated as a time-varying covariate, to avoid immortal time bias [23] . We also utilised a lag, as recommended, to remove prescriptions in the period immediately prior to death in order to minimise potential reverse causation [24] . The study design is illustrated in Fig. 1 . Individuals were regarded as furosemide nonusers until 6 months after their first prescription, at which point they were considered furosemide users until the end of follow-up. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using Cox regression models before and after adjustment for relevant confounders. The main model contained the following confounders: year of diagnosis, age at diagnosis, sex, deprivation, comorbidities (cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease, rheumatological disease and liver disease), post-diagnosis statin or aspirin use as time-varying covariates as furosemide, and cancer treatment (surgery, radiotherapy and chemotherapy within 6 months after diagnosis). An exposure-response analysis was calculated using a time-varying covariate to account for the dose and duration of use. In which, we categorised the patients as non-users (as described above), short-term users between 6 months after their first prescription and 6 months after their 365th DDD (or 12th prescription, approximately corresponding to 1 year of issued medication) and long-term users after that time. These analyses were repeated restricting the cohort to patients with any pre-diagnosis furosemide indications, described above, to attempt to reduce the impact of confounding by indication [25] . All of these analyses were conducted separately in esophageal and gastric cancer patients.
Sensitivity and subgroup analysis
Various sensitivity and subgroup analyses were conducted. We performed an analysis changing the outcome to cause of death from any cancer, and any cause. Subgroup analyses were conducted by the main histological subtypes (adenocarcinoma and SCC), among patients who underwent surgery within 6 months of diagnosis and by year of cancer diagnosis. We conducted an analysis additionally adjusting for variables which were incompletely recorded such as lifestyle exposure (smoking and alcohol conjunctively, and BMI independently), and tumor characteristics (stage and grade, separately). We conducted an analysis restricted to patients with any hypertensive medications use in the year prior to cancer diagnosis, where we removed those cases whose record period before diagnosis were less than 1 year. To further investigate potential confounding by hypertension (the most common furosemide indication before diagnosis) we conducted an active comparator analysis in which we compared furosemide users after diagnosis to users of other antihypertensive medications after diagnosis, based upon a time-varying covariate with a 6 month lag [22] . Also, we conducted an analysis extending the lag to 12 months, in which individuals who died within 12 months after diagnosis were excluded and follow-up started at 12 months. As pre-clinical evidence suggested furosemide would have a greater impact on more poorly differentiated tumor [12] , we repeated the analysis restricted to patients diagnosed with high grade (3 or 4) tumors. We also repeated the analysis for all loop diuretics (furosemide, bumetanide and torasemide) as all of them have similar NKCC inhibitor properties. Finally, to attempt to investigate the impact of furosemide on the developing tumor we conducted an analysis of furosemide use in the year before cancer diagnosis on cancer-specific mortality, in which we started to follow participants from the date of cancer diagnosis and did not exclude deaths in the first 6 months [23] . Patients with less than 1 year of records before cancer diagnosis were excluded.
Results
Overall 4799 and 4537 newly diagnosed primary esophageal and gastric cancer patients were identified in CPRD. After exclusion of patients who died within 6 months of diagnosis, there were a total of 2708 esophageal cancer cases and 2377 gastric cancer cases included in the main analyses. In these patients, the median follow-up was 1.3 years (range 0.5 to 17.2 years) for esophageal cancer and 1.5 years (range 0.5 to 17.2 years) for gastric cancer. Patient characteristics are shown in Table 1 . Furosemide users were more likely to be older (mean age at diagnosis was 75 for esophageal cancer and 77 for gastric cancer), have comorbidities (particularly HF, edema, MI, and hypertension), use statins or aspirin after diagnosis, have previously smoked and be obese (BMI ≥ 30 kg/m 2 ) compared to non-users. Other characteristics were generally similar in furosemide users and non-users, see Table 1 .
As shown in Table 2 , there was a slight increase in both esophageal and gastric cancer-specific mortality in users of furosemide compared with non-users in the primary analyses (adjusted HR in esophageal cancer = 1.28, 95% CI 1.10, 1.50 and in gastric cancer = 1.27, 95% CI 1.08, 1.50). After restricting to Table 2 ). Sensitivity analyses generally showed similar associations to the main results (Tables 3 and 4 ). In particular, associations were similar when the use of furosemide in the year before diagnosis was investigated, when a 12 month lag was used, when stratified by histological tumor subtype, when stratified by year of diagnosis, when exposure was expanded to all loop diuretics, after additional adjustment for BMI, after additional adjustment for smoking and alcohol, after additional adjustment for tumor stage or grade, and when restricted to patients diagnosed with high grade tumors. The analyses were also similar when restricting to patients who were users of any antihypertensive medications in the year prior to cancer diagnosis, and when using an active comparator to compare users of furosemide to users of other antihypertensive medications after cancer diagnosis. There was a slight increase in all-cancer and all-cause mortality in users of furosemide, compared with non-users, for both esophageal and gastric cancer patients. Furthermore, there was a slight increase in cancer-specific mortality with furosemide use when restricted to surgically treated patients (Tables 3 and 4 ).
Discussion
In this large population-based cohort we did not find evidence that furosemide was associated with a reduced risk of cancer-specific or all-cause mortality in patients with esophageal or gastric cancer. In the primary analyses, we found furosemide use was associated with slightly increased mortality in patients with esophageal or gastric cancer. However, when we restricted the analyses to patients with furosemide indications, there was little evidence of any strong association between furosemide use and deaths from esophageal or gastric cancer. Findings were similar across most subgroup and sensitivity analyses. This is, to date, the first observational study assessing the influence of furosemide use on esophageal/gastric cancer mortality. A limited number of studies have investigated furosemide use and cancer risk or survival, concentrated on investigations into breast, skin and lip cancer but not esophageal/gastric cancer, and furosemide was not the primary exposure of interest [26] [27] [28] . No consistent associations were observed for furosemide use and risk or survival of these cancers from human studies. Preclinical studies have recently shown that inhibition of the NKCC1 could slow cancer cell deterioration by influencing cancer cell growth and metastasis [11] , and furosemide could reduce cell growth in poorly differentiated gastric adenocarcinoma cells [12] . In contrast, our study did not detect any evidence that users of furosemide either before or after diagnosis of esophageal or gastric cancer had reduced cancer-specific mortality. This lack of protective effect could reflect differences in drug dose, duration of use or the recognised difficulty of in vitro models to recreate the complexity of human carcinogenesis, physiology and progression [29] .
The main strength of this study is that it utilised high quality data sources including cancer-registry records, ONS mortality data, and the CPRD for prescription data. In the UK, furosemide is only available through GP prescriptions and therefore these records are likely to capture all of the use in these populations [30] . The use of an electronic record of GP prescriptions also eliminated recall bias. In this study, we also had long-term follow-up, which makes it possible to assess the impact of furosemide on gastric or esophageal cancer prognosis long after diagnosis.
Confounding by indication is often encountered in pharmacoepidemiology studies as allocation of prescription is not randomized and the drug indication may be related to the outcomes of interest [25, 31] . We conducted a number of analyses to account for confounding by indication. Firstly, we conducted analyses restricted to patients with furosemide indications, restricted to patients with any antihypertensive medications use and an active comparator analysis comparing furosemide users to users of other antihypertensive drugs. In all of these analyses, no association between furosemide use and cancer-specific mortality was found. Although diuretics are sometimes used for malignant ascites, this is not likely to impact our results because furosemide is not commonly used for this purpose [32, 33] . Furthermore, application of the lag period removed prescriptions in the 6 months before death in the main analysis (and 12 months in sensitivity analysis), which would almost entirely remove use for ascites as survival with malignant ascites is very short [34] . Moreover, this potential weakness would not have impacted the analysis of furosemide use in the year before diagnosis, which also did not show evidence of improved survival with furosemide use. Another potential weakness is that although we were able to adjust for a wide range of confounders there is the possibility of residual confounding by incompletely recorded variables such as cancer stage and lifestyle exposures. However, based on the available data, additional adjustment of some lifestyle exposures for which we had incomplete records did not change the main findings. Also, there was no difference when analysis was restricted to poorly differentiated cancers.
Conclusion
In conclusion, in the first study to investigate furosemide use and survival in esophageal and gastric cancer patients, we did not find evidence that furosemide use was associated with improved survival.
Further preclinical or observational studies should be designed to investigate this association according to stratified analyses by tumor stage or molecular characteristics to fully exclude a potential role for this medication as an adjuvant therapy. and Healthcare Products Regulatory Agency. The CPRD collects de-identified data from a network of GP practices therefore no written informed consent was obtained. The interpretation and conclusions contained in this study are those of the authors alone.
